Energenesis Biomedical Co., Ltd.

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa	Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, epidermolysis bullosa simplex, hereditary disease, hereditary skin disorder, junctional epidermolysis bullosa, skin disorder, vesiculobullous skin disease	Recruiting	Phase 2	2026-10-05	NCT07858422
A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease	Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy	Not yet recruiting	Phase 2	2026-07-02	NCT07647614
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer	Diabetes Complications, Diabetic Foot, Foot Diseases, Foot Ulcer, Leg Ulcer, Nutritional and Metabolic Diseases, Skin Ulcer, Skin and Connective Tissue Diseases, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, glucose metabolism disease, injury, metabolic disease, skin disorder, vascular disorder	Recruiting	Phase 3	2025-10-02	NCT05930210

Clinical trials